Successful re-treatment with taxol after major hypersensitivity reactions

David M. Peereboom, Ross C Donehower, Elizabeth A. Eisenhauer, William P. McGuire, Nicole Onetto, Judith L. Hubbard, Martine Piccart, Luca Gianni, Eric K. Rowinsky

Research output: Contribution to journalArticle

Abstract

Purpose: To describe the successful re-treatment of eight patients who had major hypersensitivity reactions (HSRs) to taxol and to suggest a regimen for re-treating patients who develop major HSRs. Patients and Methods: The treatment courses of eight patients who developed major HSRs and were rechallenged with taxol were reviewed. Patients in this report represent all patients who are known to have been rechallenged with taxol after major HSRs. Results: The most common approach used to rechallenge patients consisted of premeditation with multiple high doses of corticosteroids and H1- and H2-histamine antagonists followed by the initiation of the taxol infusion at a reduced rate. All patients who experienced major HSRs were rechallenged successfully. After the rechallenge, these patients received 32 additional courses of taxol without HSRs. Conclusion: Re-treatment with taxol after major HSRs is feasible using multiple high doses of corticosteroids and antihistamine premedications and a reduced taxol infusion rate under close supervision. This approach may represent a valid alternative to the termination of taxol; however, a prospective evaluation is required to determine the true efficacy of this approach.

Original languageEnglish (US)
Pages (from-to)885-890
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Paclitaxel
Hypersensitivity
Therapeutics
Adrenal Cortex Hormones
Histamine H1 Antagonists
Histamine H2 Antagonists
Premedication
Histamine Antagonists

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Peereboom, D. M., Donehower, R. C., Eisenhauer, E. A., McGuire, W. P., Onetto, N., Hubbard, J. L., ... Rowinsky, E. K. (1993). Successful re-treatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology, 11(5), 885-890.

Successful re-treatment with taxol after major hypersensitivity reactions. / Peereboom, David M.; Donehower, Ross C; Eisenhauer, Elizabeth A.; McGuire, William P.; Onetto, Nicole; Hubbard, Judith L.; Piccart, Martine; Gianni, Luca; Rowinsky, Eric K.

In: Journal of Clinical Oncology, Vol. 11, No. 5, 1993, p. 885-890.

Research output: Contribution to journalArticle

Peereboom, DM, Donehower, RC, Eisenhauer, EA, McGuire, WP, Onetto, N, Hubbard, JL, Piccart, M, Gianni, L & Rowinsky, EK 1993, 'Successful re-treatment with taxol after major hypersensitivity reactions', Journal of Clinical Oncology, vol. 11, no. 5, pp. 885-890.
Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL et al. Successful re-treatment with taxol after major hypersensitivity reactions. Journal of Clinical Oncology. 1993;11(5):885-890.
Peereboom, David M. ; Donehower, Ross C ; Eisenhauer, Elizabeth A. ; McGuire, William P. ; Onetto, Nicole ; Hubbard, Judith L. ; Piccart, Martine ; Gianni, Luca ; Rowinsky, Eric K. / Successful re-treatment with taxol after major hypersensitivity reactions. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 5. pp. 885-890.
@article{c836ad07742f409594c75b4fc9bf6542,
title = "Successful re-treatment with taxol after major hypersensitivity reactions",
abstract = "Purpose: To describe the successful re-treatment of eight patients who had major hypersensitivity reactions (HSRs) to taxol and to suggest a regimen for re-treating patients who develop major HSRs. Patients and Methods: The treatment courses of eight patients who developed major HSRs and were rechallenged with taxol were reviewed. Patients in this report represent all patients who are known to have been rechallenged with taxol after major HSRs. Results: The most common approach used to rechallenge patients consisted of premeditation with multiple high doses of corticosteroids and H1- and H2-histamine antagonists followed by the initiation of the taxol infusion at a reduced rate. All patients who experienced major HSRs were rechallenged successfully. After the rechallenge, these patients received 32 additional courses of taxol without HSRs. Conclusion: Re-treatment with taxol after major HSRs is feasible using multiple high doses of corticosteroids and antihistamine premedications and a reduced taxol infusion rate under close supervision. This approach may represent a valid alternative to the termination of taxol; however, a prospective evaluation is required to determine the true efficacy of this approach.",
author = "Peereboom, {David M.} and Donehower, {Ross C} and Eisenhauer, {Elizabeth A.} and McGuire, {William P.} and Nicole Onetto and Hubbard, {Judith L.} and Martine Piccart and Luca Gianni and Rowinsky, {Eric K.}",
year = "1993",
language = "English (US)",
volume = "11",
pages = "885--890",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Successful re-treatment with taxol after major hypersensitivity reactions

AU - Peereboom, David M.

AU - Donehower, Ross C

AU - Eisenhauer, Elizabeth A.

AU - McGuire, William P.

AU - Onetto, Nicole

AU - Hubbard, Judith L.

AU - Piccart, Martine

AU - Gianni, Luca

AU - Rowinsky, Eric K.

PY - 1993

Y1 - 1993

N2 - Purpose: To describe the successful re-treatment of eight patients who had major hypersensitivity reactions (HSRs) to taxol and to suggest a regimen for re-treating patients who develop major HSRs. Patients and Methods: The treatment courses of eight patients who developed major HSRs and were rechallenged with taxol were reviewed. Patients in this report represent all patients who are known to have been rechallenged with taxol after major HSRs. Results: The most common approach used to rechallenge patients consisted of premeditation with multiple high doses of corticosteroids and H1- and H2-histamine antagonists followed by the initiation of the taxol infusion at a reduced rate. All patients who experienced major HSRs were rechallenged successfully. After the rechallenge, these patients received 32 additional courses of taxol without HSRs. Conclusion: Re-treatment with taxol after major HSRs is feasible using multiple high doses of corticosteroids and antihistamine premedications and a reduced taxol infusion rate under close supervision. This approach may represent a valid alternative to the termination of taxol; however, a prospective evaluation is required to determine the true efficacy of this approach.

AB - Purpose: To describe the successful re-treatment of eight patients who had major hypersensitivity reactions (HSRs) to taxol and to suggest a regimen for re-treating patients who develop major HSRs. Patients and Methods: The treatment courses of eight patients who developed major HSRs and were rechallenged with taxol were reviewed. Patients in this report represent all patients who are known to have been rechallenged with taxol after major HSRs. Results: The most common approach used to rechallenge patients consisted of premeditation with multiple high doses of corticosteroids and H1- and H2-histamine antagonists followed by the initiation of the taxol infusion at a reduced rate. All patients who experienced major HSRs were rechallenged successfully. After the rechallenge, these patients received 32 additional courses of taxol without HSRs. Conclusion: Re-treatment with taxol after major HSRs is feasible using multiple high doses of corticosteroids and antihistamine premedications and a reduced taxol infusion rate under close supervision. This approach may represent a valid alternative to the termination of taxol; however, a prospective evaluation is required to determine the true efficacy of this approach.

UR - http://www.scopus.com/inward/record.url?scp=0027315849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027315849&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 885

EP - 890

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -